Nicotine improves working memory span capacity in rats following sub-chronic ketamine exposure

Neuropsychopharmacology

Volumn 36, Issue 13, 2011, Pages 2774-2781

  Rushforth, Samantha L ^a   Steckler, Thomas ^b   Shoaib, Mohammed ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

clozapine; ketamine; LY404039; nicotine; odor span task; working memory

Indexed keywords

4 AMINO 2 THIABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID 2,2 DIOXIDE; CLOZAPINE; KETAMINE; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; MALE; NONHUMAN; ODOR; ODOR SPAN TASK; PERFORMANCE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; TASK PERFORMANCE; WORKING MEMORY; WORKING MEMORY SPAN CAPACITY;

ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; KETAMINE; MALE; MEMORY, SHORT-TERM; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, INBRED STRAINS;

EID: 80855123524     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.224     Document Type: Article

References (64)

1. Abdul-Monim Z, Reynolds GP, Neill JC (2006). The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 169: 263-273.
2. Addy N, Levin E (2002). Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 27: 534-541.
3. Anis N, Berry S, Burton N, Lodge D (1983). The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol 79: 565-575. (Pubitemid 13055426)
4. Atzori G, Lemmonds CA, Kotler ML, Durcan MJ, Boyle J (2008). Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal. J Clin Psychopharmacol 28: 667-674.
5. Barr R, Culhane M, Jubelt L (2008). The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33: 480-490.
6. Baviera M, Invernizzi RW, Carli M (2008). Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl) 196: 269-280.
7. Becker A, Peters B, Schroeder H (2003). Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 687-700. (Pubitemid 36645072)
8. Bidzan L (2007). A review of the effects of nicotine on schizophrenia. Psychiatr Pol 41: 737-744.
9. Buccafusco JJ, Terry Jr AV (2009). A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 78: 852-862.
10. Buchanan RW, Davis M, Goff D, Green MF, Keefe RS, Leon AC et al (2005). A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 31: 5-19. (Pubitemid 41214353)
11. Dade L, Zatorre R, Evans A, Jones-Gotman M (2001). Working memory in another dimension: functional imaging of human olfactory working memory. NeuroImage 14: 650-660. (Pubitemid 32801712)
12. Dalley J, Cardinal R, Robbins T (2004). Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 28: 771-784. (Pubitemid 39535871)
13. Dudchenko PA, Wood ER, Eichenbaum H (2000a). Neurotoxic hippocampal lesions have no effect on odor span and little effect on odor recognition memory but produce significant impairments on spatial span, recognition and alternation. J Neurosci 20: 2964-2977. (Pubitemid 30220322)
14. Dudchenko PA, Wood ER, Eichenbaum H (2000b). Neurotoxic hippocampal lesions have no effect on odor span and little effect on odor recognition memory but produce significant impairments on spatial span, recognition, and alternation. J Neurosci 20: 2964-2977. (Pubitemid 30220322)
15. Foulds J, Stapleton J, Swettenham J, Bell N, McSorley K, Russell MA (1996). Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. Psychopharmacology (Berl) 127: 31-38. (Pubitemid 26285680)
16. Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L et al (2008). Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 165: 1040-1047.
17. Froeliger B, Gilbert DG, McClernon FJ (2009). Effects of nicotine on novelty detection and memory recognition performance: double-blind, placebo-controlled studies of smokers and non-smokers. Psychopharmacology (Berl) 205: 625-633.
18. George T, Vessicchio J, Termine A, Sahady D (2002). Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 26: 75-85. (Pubitemid 34075278)
19. Ghoneim M, Hinrichs J, Mewaldt S, Petersen R (1985). Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharma-col 5: 70-77. (Pubitemid 15149495)
20. Gold JM, Hahn B, Zhang WW, Robinson BM, Kappenman ES, Beck VM et al (2010). Reduced capacity but spared precision and maintenance of working memory representations in schizophrenia. Arch Gen Psychiatry 67: 570-577.
21. Granon S, Poucet B, Thinus-Blanc C, Changeux JP, Vidal C (1995). Nicotinic and muscarinic receptors in the rat prefrontal cortex: differential roles in working memory, response selection and effortful processing. Psychopharmacology (Berl) 119: 139-144.
22. Gray G, van den Buuse M, Scarr E (2009). Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharma-col 12: 45-60.
23. Groenewegen H, Uylings H (2000). The prefrontal cortex and the integration of sensory, limbic and autonomic information. Prog Brain Res 126: 3-28. (Pubitemid 35461278)
24. Jacobsen L, D'Souza D, Mencl W, Pugh K, Skudlarski P, Krystal J (2004). Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry 55: 850-858. (Pubitemid 38429877)
25. Javitt D (1999). Treatment of negative and cognitive symptoms. Curr Psychiatry Rep 1: 25-30.
26. Jedema HP, Moghddam B (1996). Characterization of excitatory amino acid modulation of dopamine release in the prefrontal cortex of conscious rats. J Neurochem 66: 1448-1453. (Pubitemid 26090547)
27. Kinoshita S, Yokoyama C, Masaki D (2008). Effects of rat medial prefrontal cortex lesions on olfactory serial reversal and delayed alternation tasks. Neurosci Res 60: 213-218.
28. Krystal J, Karper L, Seibyl J, Freeman G, Delaney R, Bremner J et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214. (Pubitemid 24081509)
29. Krystal J, Perry EJ, Gueorguieva R (2005). Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62: 985-994.
30. Laroche S, Davis S, Jay T (2000). Plasticity at hippocampal to prefrontal cortex synapses: dual roles in working memory and consolidation. Hippocampus 10: 438-446.
31. Laroche S, Jay T, Thierry A (1990). Long-term potentiation in the prefrontal cortex following stimulation of the hippocampal CA1/subicular region. Neurosci Lett 114: 184-190. (Pubitemid 20188955)
32. Levin E (1992). Nicotinic systems and cognitive function. Psychopharmacology (Berl) 108: 417-431.
33. Levin E, Christopher N (2006). Effects of clozapine on memory function in the rat neonatal hippocampal lesion model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 30: 223-229. (Pubitemid 43288062)
34. Levin E, Kaplan S, Boardman A (1997). Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol 8: 236-242. (Pubitemid 27303918)
35. Levin E, Kim P, Meray R (1996). Chronic nicotine effects on working and reference memory in the 16-arm radial maze: interactions with D1 agonist and antagonist drugs. Psychophar-macology (Berl) 127: 25-30. (Pubitemid 26285679)
36. Levin E, McClernon F, Rezvani A (2006). Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl) 184: 523-539. (Pubitemid 43255869)
37. Levin ED, Bettegowda C, Weaver T, Christopher NC (1998). Nicotine-dizocilpine interactions and working and reference memory performance of rats in the radial-arm maze. Pharmacol Biochem Behav 61: 335-340. (Pubitemid 28498217)
38. Levin ED, Rezvani AH (2006). Nicotinic-antipsychotic drug interactions and cognitive function. EXS 98: 185-205.
39. Luby E, Cohen B, Rosenbaum F, Gottlieb J, Kelley R (1959). Study of a new schizophrenomimetic drug, Sernyl. Arch Neurol Psychiatry 81: 363-369.
40. Malhotra A, Pinals D, Adler C, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150. (Pubitemid 27365955)
41. Malhotra A, Pinals D, Weingartner H (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307. (Pubitemid 26151927)
42. Meltzer H, McGurk S (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schi-zophr Bull 25: 233-255. (Pubitemid 29272503)
43. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927. (Pubitemid 27155025)
44. Murphy B, Roth R, Arnsten A (1997). Clozapine reverses the spatial working memory deficits induced by FG7142 in monkeys. Neuropsychopharmacology 16: 433-437. (Pubitemid 27244449)
45. Murray JB (2002). Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research. J Psychol 136: 319-327.
46. Nabeshima T, Mouri A, Murai R, Noda Y (2006). Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phency-clidine. Ann NY Acad Sci 1086: 160-168. (Pubitemid 47084371)
47. Newcomer J, Farber N, Jevtovic-Todorovic V (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118. (Pubitemid 29010370)
48. Newhouse PA, Potter A, Singh A (2004). Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol 4: 36-46. (Pubitemid 38145836)
49. Parwani A, Weiler M, Blaxton T, Warfel D, Hardin M, Frey K et al (2005). The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. Psychopharmacology (Berl) 183: 265-274. (Pubitemid 41660411)
50. Patil S, Zhang L, Martenyi F, Lowe S, Jackson K (2007). Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nature Medicine 13: 1102-1107. (Pubitemid 47517511)
51. Perala J, Suvisaari J, Saarni S, Kuoppasalmi K, Isometsä E, Pirkola S (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 64: 19-28. (Pubitemid 46041735)
52. Pocivavsek A, Laura Icenogle L, Levin E (2006). Ventral hippocampal a7 and a4b2 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology 188: 597-604. (Pubitemid 46758963)
53. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW et al (2007). In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 193: 121-136. (Pubitemid 46906627)
54. Rosenheck R, Dunn L, Peszke M (1999). Impact of clozapine on negative symptoms and on the deficit syndrome in refractory schizophrenia. Am J Psychiatry 156: 88-93. (Pubitemid 29034884)
55. Rushforth SL, Allison C, Wonnacott S, Shoaib M (2010). Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci Lett 471: 114-118.
56. Smith R, Singh A, Infante M, Khandat A (2002). Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 27: 479-497. (Pubitemid 35253795)
57. Smith R, Warner-Cohen J, Matute M, Butler E, Kelly E (2006). Effects of nicotine nasal spray on cognitive function in schizophrenia. Neuropsychopharmacology 31: 637-643. (Pubitemid 43276979)
58. Turchi J, Sarter M (2000). Cortical cholinergic inputs mediate processing capacity: effects of 192 IgG-saporin-induced lesions on olfactory span performance. Eur J Neurosci 12: 4505-4514. (Pubitemid 32037858)
59. Verma A, Moghaddam B (1996). The role of excitatory amino acids in prefrontal cortex function as assessed by spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16: 373-379. (Pubitemid 26010723)
60. Weinberger D, Gallhofer B (1997). Cognitive function in schizophrenia. Int Clin Psychopharmacol 12: S29-S36. (Pubitemid 27414441)
61. Yoon T, Okada J, Jung M (2008). Prefrontal cortex and hippocampus subserve different components of working memory in rats. Learn Mem 19: 97-105. (Pubitemid 351439139)
62. Young JW, Crawford N, Kelly JS, Kerr LE, Marston HM, Spratt C et al (2007b). Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsycho-pharmacol 17: 145-155. (Pubitemid 44802833)
63. Young JW, Kerr LE, Kelly JS, Marston HM, Spratt C, Finlayson K et al (2007a). The odour span task: a novel paradigm for assessing working memory in mice. Neuropharmacology 52: 634-645. (Pubitemid 46137979)
64. Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Pinto AG et al (2009). Cognitive performance and cigarette smoking in first-episode psychosis. Eur Arch Psychiatry Clin Neurosci 259: 65-71.